A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma

Uveal melanoma (UM) is a rare subset of melanoma characterized by the presence of early initiating GNAQ/11 mutations, with downstream activation of the PKC, MAPK, and PI3Kα pathways. Activity has been observed with the PKC inhibitors sotrastaurin (AEB071) and darovasertib (IDE196) in patients with U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander N. Shoushtari, Shaheer Khan, Kimberly Komatsubara, Lynn Feun, Nicolas Acquavella, Shahnaz Singh-Kandah, Tiffany Negri, Alexandra Nesson, Kelly Abbate, Serge Cremers, Elgilda Musi, Grazia Ambrosini, Shing Lee, Gary K. Schwartz, Richard D. Carvajal
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	uveal melanoma targeted therapy sotrastaurin alpelisib PKC PI3K Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ca14021bac2d473688895d4925fe502f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma

Ejemplares similares